Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Matters Arising
  • Published:

Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection

Nature Microbiology volume 5, page 236 (2020)Cite this article

Subjects

Matters Arising to this article was published on 27 January 2020

The Original Article was published on 12 August 2019

Access through your institution
Buy or subscribe

arising from Y. N. Srikhanta et al. Nature Microbiology https://doi.org/10.1038/s41564-019-0519-1 (2019)

In their Article, Srikhanta et al.1 suggest that cephamycin antibiotics can be used to treat recurrent Clostridioides difficile infection (CDI) through the inhibition of sporulation. We are concerned that, on the basis of existing data, the use of cephamycins for CDI may not be appropriate.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Srikhanta, Y. N. et al. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection. Nat. Microbiol. 4, 2237–2245 (2019).

    Article  Google Scholar 

  2. Carignan, A. et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin. Infect. Dis. 46, 1838–1843 (2008).

    Article  Google Scholar 

  3. Block, B. S. et al. Clostridium difficile-associated diarrhea follows perioperative prophylaxis with cefoxitin. Am. J. Obstet. Gynecol. 153, 835–838 (1985).

    Article  CAS  Google Scholar 

  4. Kent, K. C. et al. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. Ann. Surg. 227, 296–301 (1998).

    Article  CAS  Google Scholar 

  5. Crabtree, T. D. et al. Clinical characteristics and antibiotic utilization in surgical patients with Clostridium difficile-associated diarrhea. Am. Surgeon 65, 507–511 (1999).

    CAS  PubMed  Google Scholar 

  6. Turner, M. C. et al. Multidisciplinary approach to Clostridium difficile infection in adult surgical patients. J. Am. Coll. Surgeons 228, 570–580 (2019).

    Article  Google Scholar 

  7. Stiefel, U. et al. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect. Cont. Hosp. Epidemiol. 25, 373–379 (2004).

    Article  Google Scholar 

  8. Barza, M. et al. Effect of broad-spectrum parenteral antibiotics on “colonization resistance” of intestinal microflora of humans. Antimicrob. Agents Chemother. 31, 723–727 (1987).

    Article  CAS  Google Scholar 

  9. Giuliano, M. et al. Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans. Antimicrob. Agents Chemother. 31, 202–206 (1987).

    Article  CAS  Google Scholar 

  10. Nerandzic, M. M. & Donskey, C. J. Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice. Antimicrob. Agents Chemother. 55, 2174–2177 (2011).

    Article  CAS  Google Scholar 

  11. Rice, L. B. et al. β-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci. J. Infect. Dis. 189, 1113–1118 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and UK Clostridium difficile Reference Laboratory, Leeds Teaching Hospitals and University of Leeds, Leeds, UK

    Mark H. Wilcox

Authors
  1. Mark H. Wilcox
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mark H. Wilcox.

Ethics declarations

Competing interests

M.H.W. has received research funding and/or consultancy funding from several companies developing CDI treatment/prevention therapeutics, including Astellas, Da Volterra, Merck, Pfizer, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics, Valneva and Vaxxilon.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilcox, M.H. Caution is warranted in using cephamycin antibiotics against recurrent Clostridioides difficile infection. Nat Microbiol 5, 236 (2020). https://doi.org/10.1038/s41564-019-0661-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41564-019-0661-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology